|
🐜
|
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
38 auth.
M. Palafox,
L. Monserrat,
M. Bellet,
G. Villacampa,
A. González-Pérez,
Mafalda Oliveira,
F. Brasó-Maristany,
Nusaibah Ibrahimi,
S. Kannan,
L. Mina,
M. T. Herrera-Abreu,
Andreu Òdena,
M. Sánchez-Guixé,
M. Capelán,
A. Azaro,
...
A. Bruna,
O. Rodríguez,
M. Guzman,
J. Grueso,
C. Viaplana,
Javier Hernández,
F. Su,
Kui Lin,
R. Clarke,
C. Caldas,
J. Arribas,
S. Michiels,
A. García-Sanz,
N. Turner,
A. Prat,
P. Nuciforo,
R. Dienstmann,
C. Verma,
N. López-Bigas,
M. Scaltriti,
M. Arnedos,
C. Saura,
V. Serra
|
5 |
2021 |
5
🐜
|
|
🐜
|
Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs
11 auth.
Jennifer L. Green,
E. Okerberg,
Josilyn Sejd,
M. Palafox,
L. Monserrat,
Senait Alemayehu,
...
Jiangyue Wu,
Maria Sykes,
A. Aban,
V. Serra,
T. Nomanbhoy
|
4 |
2019 |
4
🐜
|
|
🐜
|
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts
31 auth.
Albert Gris-Oliver,
M. Palafox,
L. Monserrat,
F. Brasó-Maristany,
Andreu Òdena,
M. Sánchez-Guixé,
Y. Ibrahim,
G. Villacampa,
J. Grueso,
M. Parés,
M. Guzman,
O. Rodríguez,
A. Bruna,
C. Hirst,
A. Barnicle,
...
E. D. de Bruin,
A. Reddy,
G. Schiavon,
J. Arribas,
G. Mills,
C. Caldas,
R. Dienstmann,
A. Prat,
P. Nuciforo,
P. Razavi,
M. Scaltriti,
N. Turner,
C. Saura,
B. Davies,
Mafalda Oliveira,
V. Serra
|
4 |
2020 |
4
🐜
|
|
🐜
|
Cytomegalovirus colitis mimicking a colonic neoplasm or ischemic colitis 4 years after heart transplantation.
10 auth.
M. Crespo,
F. Arnal,
M. Gómez,
L. Monserrat,
F. Suárez,
J. Rodríguez,
...
M. Paniagua,
M. Cuesta,
A. Juffé,
A. Castro‐Beiras
|
4 |
1998 |
4
🐜
|
|
🐜
|
Abstract P5-13-14: Antitumor activity of patritumab deruxtecan (HER3-DXd), a HER3-directed antibody drug conjugate (ADC) across a diverse panel of breast cancer (BC) patient-derived xenografts (PDXs)
13 auth.
Andreu Òdena,
L. Monserrat,
F. Brasó-Maristany,
M. Guzman,
J. Grueso,
O. Rodríguez,
Maurizio Scaltriti,
S. Chandarlapaty,
Yang Qiu,
K. Koyama,
...
Mafalda Oliveira,
A. Prat,
V. Serra
|
1 |
2022 |
1
🐜
|
|
🐜
|
Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
38 auth.
M. Palafox,
L. Monserrat,
M. Bellet,
G. Villacampa,
A. González-Pérez,
Mafalda Oliveira,
F. Brasó-Maristany,
Nusaibah Ibrahimi,
S. Kannan,
L. Mina,
M. T. Herrera-Abreu,
Andreu Òdena,
M. Sánchez-Guixé,
M. Capelán,
A. Azaro,
...
A. Bruna,
O. Rodríguez,
M. Guzman,
J. Grueso,
C. Viaplana,
Javier Hernández,
F. Su,
Kui Lin,
R. Clarke,
C. Caldas,
J. Arribas,
S. Michiels,
A. García-Sanz,
N. Turner,
A. Prat,
P. Nuciforo,
R. Dienstmann,
C. Verma,
N. López-Bigas,
Maurizio Scaltriti,
M. Arnedos,
C. Saura,
V. Serra
|
0 |
2022 |
0
🐜
|
